OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Subscribe To Our Newsletter & Stay Updated
